Physician profile
Madison Flicker
NPI 1881390730
$884.65
in general payments reported to CMS, 2019-2025
15 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $199 · 2024: $451 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $885.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $884.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $204.10 | 2023-2025 | Repatha, Otezla, Otezla |
| Astrazeneca Pharmaceuticals LP | $113.50 | 2023-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.14 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Esperion Therapeutics, INC. | $77.58 | 2024-2025 | Nexletol |
| Novo Nordisk INC | $67.70 | 2023-2025 | Rybelsus, Ozempic |
| Seqirus USA INC | $64.61 | 2024-2025 | Flucelvax, Fluad |
| Pfizer INC. | $60.06 | 2023-2024 | |
| Astellas Pharma US INC | $53.36 | 2023 | Veozah |
| Edwards Lifesciences Corporation | $34.04 | 2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Lilly USA, LLC | $28.99 | 2024 | Mounjaro, Zepbound |
| Abbvie INC. | $19.59 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.85 | 2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $14.47 | 2024 | Trintellix |
| Idorsia Pharmaceuticals US INC | $14.09 | 2024 | Quviviq |
| Sumitomo Pharma America, INC. | $13.57 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Flicker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.